Adarsh Vennepureddy - Hematologist ...

Dr. Adarsh Vennepureddy

Claim this profile

Aultman Health Foundation

Studies Colorectal Cancer
Studies Colon Cancer
9 reported clinical trials
30 drugs studied

Area of expertise

1Colorectal Cancer
Adarsh Vennepureddy has run 3 trials for Colorectal Cancer. Some of their research focus areas include:
Stage III
Stage II
MLH1 positive
2Colon Cancer
Adarsh Vennepureddy has run 2 trials for Colon Cancer. Some of their research focus areas include:
Stage III
Stage II
MLH1 positive

Affiliated Hospitals

Image of trial facility.
Aultman Health Foundation
Image of trial facility.
Aultman Alliance Community Hospital

Clinical Trials Adarsh Vennepureddy is currently running

Image of trial facility.

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
Image of trial facility.

Ipatasertib + Chemotherapy

for Cancer

This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2

More about Adarsh Vennepureddy

Clinical Trial Related2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Adarsh Vennepureddy has experience with
  • Binimetinib
  • Fulvestrant
  • Paclitaxel
  • Oxaliplatin
  • Selumetinib Sulfate
  • Ipatasertib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Adarsh Vennepureddy specialize in?
Is Adarsh Vennepureddy currently recruiting for clinical trials?
Are there any treatments that Adarsh Vennepureddy has studied deeply?
What is the best way to schedule an appointment with Adarsh Vennepureddy?
What is the office address of Adarsh Vennepureddy?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security